Workflow
Nuvalent(NUVL)
icon
Search documents
Nuvalent: A Logical Acquisition Target
Seeking Alpha· 2025-01-10 18:22
Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been roughly six months since my last Nuvalent (NASDAQ: NUVL ) article , where I discussed NVL-655’s blockbuster potential following the FDA’s decision to grant the company’s ALK-selective inhibitor, NVL-655 their Breakthrough Therapy Designation ...
Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Prnewswire· 2024-12-19 11:30
CAMBRIDGE, Mass., Dec. 19, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 9:00 a.m. PT in San Francisco.  A live webcast will be available in the Investors section of the company's website at www.nuval ...
Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference
Prnewswire· 2024-11-26 11:52
CAMBRIDGE, Mass, Nov. 26, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 3:30 p.m. ET in NYC.A live webcast will be available ...
Nuvalent(NUVL) - 2024 Q3 - Quarterly Report
2024-11-12 11:42
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |------------------------------------------------------------------------------------------------------|--------------------------------------------------- ...
Nuvalent(NUVL) - 2024 Q3 - Quarterly Results
2024-11-12 11:38
Exhibit 99.1 Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results Achievement of all anticipated 2024 milestones and accelerated development timelines reinforce progress on OnTarget 2026 operating plan towards first approved product in 2026 Leading medical oncologist Alice Shaw, M.D., Ph.D. appointed to Scientific Advisory Board Strong cash position of $1.2 billion, including proceeds from upsized $575 million public ...
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
Prnewswire· 2024-11-12 11:30
Achievement of all anticipated 2024 milestones and accelerated development timelines reinforce progress on OnTarget 2026 operating plan towards first approved product in 2026Leading medical oncologist Alice Shaw, M.D., Ph.D. appointed to Scientific Advisory BoardStrong cash position of $1.2 billion, including proceeds from upsized $575 million public offering, expected to extend operating runway into 2028CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharm ...
Nuvalent: Promising Data Keeps Validating Pipeline And Platform
Seeking Alpha· 2024-09-23 16:34
Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Although there are no personal account positions, SOME STOCKS MENTIONED CAN ALREADY BE PART OF THE PO ...
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
Prnewswire· 2024-09-18 20:05
CAMBRIDGE, Mass., Sept. 18, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its previously announced upsized underwritten public offering of 5,750,000 shares of Class A common stock, which includes 750,000 shares of Class A common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional sha ...
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
ZACKS· 2024-09-18 19:31
Shares of Nuvalent (NUVL) have soared nearly 20% in the past week owing to encouraging updates on its two investigational therapies. Both therapies target previously treated non-small cell lung cancer (NSCLC) patients but focus on different genetic mutations. These updates were announced earlier this weekend at the European Society for Medical Oncology (ESMO) Congress 2024 meeting held in Spain. NUVL Boasts Encouraging Pipeline Potential in NSCLC Space Management presented updated data from the early-stage ...
Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases
Seeking Alpha· 2024-09-17 17:20
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...